These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17330097)

  • 1. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.
    Griessinger E; Imbert V; Lagadec P; Gonthier N; Dubreuil P; Romanelli A; Dreano M; Peyron JF
    Leukemia; 2007 May; 21(5):877-85. PubMed ID: 17330097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
    Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.
    Griessinger E; Frelin C; Cuburu N; Imbert V; Dageville C; Hummelsberger M; Sirvent N; Dreano M; Peyron JF
    Leukemia; 2008 Jul; 22(7):1466-9. PubMed ID: 18239622
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
    Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
    Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.
    Wang C; Lu J; Wang Y; Bai S; Wang Y; Wang L; Sheng G
    J Biochem Mol Toxicol; 2012 Jan; 26(1):35-43. PubMed ID: 21928377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
    Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
    Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Grosjean-Raillard J; Adès L; Boehrer S; Tailler M; Fabre C; Braun T; De Botton S; Israel A; Fenaux P; Kroemer G
    Apoptosis; 2008 Sep; 13(9):1148-61. PubMed ID: 18670883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
    Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
    Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
    Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
    Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
    Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM
    Oncotarget; 2016 Jul; 7(30):47465-47478. PubMed ID: 27329844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.
    Muranyi AL; Dedhar S; Hogge DE
    Leuk Res; 2010 Oct; 34(10):1358-65. PubMed ID: 20193963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
    Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
    Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 inhibitors in acute myeloid leukemia.
    el-Shami K; Stone RM; Smith BD
    Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.